Literature DB >> 23528339

Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study.

Tonya Adamiak1, Dorota Walkiewicz-Jedrzejczak, Daryl Fish, Christopher Brown, Jeanne Tung, Khalid Khan, William Faubion, Roger Park, Janice Heikenen, Michael Yaffee, Maria T Rivera-Bennett, Marcy Wiedkamp, Michael Stephens, Richard Noel, Melodee Nugent, Justin Nebel, Pippa Simpson, Michael D Kappelman, Subra Kugathasan.   

Abstract

BACKGROUND: Epidemiological studies of pediatric inflammatory bowel diseases (IBD) are needed to generate etiological hypotheses and inform public policy; yet, rigorous population-based studies of the incidence and natural history of Crohn's disease (CD) and ulcerative colitis (UC) in the United States are limited.
METHODS: We developed a field-tested prospective system for identifying all new cases of IBD among Wisconsin children over an 8-year period (2000-2007). Subsequently, at the end of the study period, we retrospectively reconfirmed each case and characterized the clinical course of this incident cohort.
RESULTS: The annual incidence of IBD among Wisconsin children was 9.5 per 100,000 (6.6 per 100,000 for CD and 2.4 per 100,000 for UC). Approximately 19% of incident cases occurred in the first decade of life. Over the 8-year study period, the incidence of both CD and UC remained relatively stable. Additionally, (1) childhood IBD affected all racial groups equally, (2) over a follow-up of 4 years, 17% of patients with CD and 13% of patients with patients with UC required surgery, and (3) 85% and 40% of children with CD were treated with immunosuppressives and biologics, respectively, compared with 62% and 30% of patients with UC.
CONCLUSIONS: As in other North American populations, these data confirm a high incidence of pediatric-onset IBD. Importantly, in this Midwestern U.S. population, the incidence of CD and UC seems to be relatively stable over the last decade. The proportions of children requiring surgery and undergoing treatment with immunosuppressive and biological medications underscore the burden of these conditions.

Entities:  

Mesh:

Year:  2013        PMID: 23528339      PMCID: PMC4898969          DOI: 10.1097/MIB.0b013e318280b13e

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  22 in total

1.  Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006.

Authors:  Oren Abramson; Michael Durant; William Mow; Allen Finley; Pratima Kodali; Anthony Wong; Venessa Tavares; Erin McCroskey; Liyan Liu; James D Lewis; James E Allison; Nicole Flowers; Susan Hutfless; Fernando S Velayos; Geraldine S Perry; Robert Cannon; Lisa J Herrinton
Journal:  J Pediatr       Date:  2010-04-18       Impact factor: 4.406

Review 2.  Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature.

Authors:  Maria Bai; Konstantinos H Katsanos; Michael Economou; Sevasti Kamina; Christine Balli; Evangelos Briasoulis; Angelos M Kappas; Niki Agnantis; Epameinondas V Tsianos
Journal:  Scand J Gastroenterol       Date:  2006-07       Impact factor: 2.423

3.  The epidemiology of inflammatory bowel disease in Canada: a population-based study.

Authors:  Charles N Bernstein; Andre Wajda; Lawrence W Svenson; Adrian MacKenzie; Mieke Koehoorn; Maureen Jackson; Richard Fedorak; David Israel; James F Blanchard
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

4.  Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.

Authors:  Ann Corken Mackey; Lanh Green; Li-Ching Liang; Patricia Dinndorf; Mark Avigan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-02       Impact factor: 2.839

5.  The burden of inflammatory bowel disease in the United States: a moving target?

Authors:  Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2007-12       Impact factor: 11.382

6.  Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease.

Authors:  James Markowitz; Jeffrey Hyams; David Mack; Neal Leleiko; Jonathan Evans; Subra Kugathasan; Marian Pfefferkorn; Adam Mezoff; Joel Rosh; Vasundhara Tolia; Anthony Otley; Anne Griffiths; M Susan Moyer; Maria Oliva-Hemker; Robert Wyllie; Robert Rothbaum; Athos Bousvaros; J Fernando Del Rosario; Sandra Hale; Trudy Lerer
Journal:  Clin Gastroenterol Hepatol       Date:  2006-07-24       Impact factor: 11.382

7.  Rising incidence of inflammatory bowel disease among children: a 12-year study.

Authors:  Hoda M Malaty; Xiaolin Fan; Antone R Opekun; Carolyn Thibodeaux; George D Ferry
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-01       Impact factor: 2.839

8.  Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study.

Authors:  Subra Kugathasan; Robert H Judd; Raymond G Hoffmann; Janice Heikenen; Gregorz Telega; Farhat Khan; Sally Weisdorf-Schindele; William San Pablo; Jean Perrault; Roger Park; Michael Yaffe; Christopher Brown; Maria T Rivera-Bennett; Issam Halabi; Alfonso Martinez; Ellen Blank; Steven L Werlin; Colin D Rudolph; David G Binion
Journal:  J Pediatr       Date:  2003-10       Impact factor: 4.406

9.  Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.

Authors:  Sarah Caspersen; Margarita Elkjaer; Lene Riis; Natalia Pedersen; Christian Mortensen; Tine Jess; Pernille Sarto; Tanja S Hansen; Vibeke Wewer; Flemming Bendtsen; Flemming Moesgaard; Pia Munkholm
Journal:  Clin Gastroenterol Hepatol       Date:  2008-10-09       Impact factor: 11.382

10.  Age and family history at presentation of pediatric inflammatory bowel disease.

Authors:  Toba A Weinstein; Mindy Levine; Michael J Pettei; David M Gold; Bradley H Kessler; Jeremiah J Levine
Journal:  J Pediatr Gastroenterol Nutr       Date:  2003-11       Impact factor: 2.839

View more
  33 in total

1.  A baseline assessment of enhanced recovery protocol implementation at pediatric surgery practices performing inflammatory bowel disease operations.

Authors:  Jonathan Vacek; Teaniese Davis; Benjamin T Many; Sharron Close; Sarah Blake; Yue-Yung Hu; Jane L Holl; Julie Johnson; Jennifer Strople; Mehul V Raval
Journal:  J Pediatr Surg       Date:  2020-06-27       Impact factor: 2.545

2.  NOD2 gene mutations in ulcerative colitis: useless or misunderstood?

Authors:  Paulo Freire; Ricardo Cardoso; Pedro Figueiredo; Maria M Donato; Manuela Ferreira; Sofia Mendes; Ana Margarida Ferreira; Helena Vasconcelos; Francisco Portela; Carlos Sofia
Journal:  Int J Colorectal Dis       Date:  2014-03-22       Impact factor: 2.571

3.  Incidence and Prevalence of Crohn's Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010.

Authors:  Raina Shivashankar; William J Tremaine; W Scott Harmsen; Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2016-11-14       Impact factor: 11.382

Review 4.  Medical and Surgical Management of Pediatric Ulcerative Colitis.

Authors:  José M Cabrera; Thomas T Sato
Journal:  Clin Colon Rectal Surg       Date:  2018-02-25

5.  Colectomies in children with inflammatory bowel disease: a national referral centre experience.

Authors:  Ancuta Muntean; Ionica Stoica; Suzanne Victoria McMahon; Alan Mortell; John Gillick; Brian Terence Sweeney
Journal:  Pediatr Surg Int       Date:  2019-03-07       Impact factor: 1.827

6.  Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients.

Authors:  Michael J Rosen; Rebekah Karns; Jefferson E Vallance; Ramona Bezold; Amanda Waddell; Margaret H Collins; Yael Haberman; Phillip Minar; Robert N Baldassano; Jeffrey S Hyams; Susan S Baker; Richard Kellermayer; Joshua D Noe; Anne M Griffiths; Joel R Rosh; Wallace V Crandall; Melvin B Heyman; David R Mack; Michael D Kappelman; James Markowitz; Dedrick E Moulton; Neal S Leleiko; Thomas D Walters; Subra Kugathasan; Keith T Wilson; Simon P Hogan; Lee A Denson
Journal:  Gastroenterology       Date:  2017-01-26       Impact factor: 22.682

Review 7.  Approach to a Child with Colitis.

Authors:  Sirish K Palle; Mahadev Prasad; Subra Kugathasan
Journal:  Indian J Pediatr       Date:  2016-04-15       Impact factor: 1.967

Review 8.  Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.

Authors:  Millie D Long; Susan Hutfless; Michael D Kappelman; Hamed Khalili; Gilaad G Kaplan; Charles N Bernstein; Jean Frederic Colombel; Corinne Gower-Rousseau; Lisa Herrinton; Fernando Velayos; Edward V Loftus; Geoffrey C Nguyen; Ashwin N Ananthakrishnan; Amnon Sonnenberg; Andrew Chan; Robert S Sandler; Ashish Atreja; Samir A Shah; Kenneth J Rothman; Neal S Leleiko; Renee Bright; Paolo Boffetta; Kelly D Myers; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

Review 9.  Diagnosis and management of inflammatory bowel disease in children.

Authors:  Stephanie B Oliveira; Iona M Monteiro
Journal:  BMJ       Date:  2017-05-31

Review 10.  Microbiome-Epigenome Interactions and the Environmental Origins of Inflammatory Bowel Diseases.

Authors:  Tatiana Y Fofanova; Joseph F Petrosino; Richard Kellermayer
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-02       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.